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Background: Targeting signaling pathways is an attractive approach in many malignancies. The PI3K/Akt/mTOR
pathway is activated in a number of human neoplasms, accompanied by lower overall and/or disease free survival.
mTOR kinase inhibitors have been introduced in the therapy of renal cell carcinoma and mantle cell lymphoma,
and several trials are currently underway. However, the pathological characterization of mTOR activity in lymphomas
is still incomplete.
Methods: mTOR activity and the elements of mTOR complexes were investigated by immunohistochemistry on
tissue microarrays representing different human non-Hodgkin-lymphomas (81 cases) and Hodgkin-lymphomas (87
cases). The expression of phospho-mTOR, phospho-4EBP1, phospho-p70S6K, phospho-S6, Rictor, Raptor and Bcl-2,
Bcl-xL, Survivin and NF-kappaB-p50 were evaluated, and mTOR activity was statistically analyzed along with 5-year
survival data. The in vitro and in vivo effect of the mTOR inhibitor rapamycin was also examined in human
Hodgkin-lymphoma cell lines.
Results: The majority (>50%) of mantle cell lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, anaplastic
large-cell lymphoma and Hodgkin-lymphoma cases showed higher mTOR activity compared to normal lymphoid
tissues. Hodgkin-lymphoma was characterized by high mTOR activity in 93% of the cases, and Bcl-xL and
NF-kappaB expression correlated with this mTOR activity. High mTOR activity was observed in the case of both
favorable and unfavorable clinical response. Low mTOR activity was accompanied by complete remission and at
least 5-year disease free survival in Hodgkin-lymphoma patients. However, statistical analysis did not identify
correlation beetween mTOR activity and different clinical data of HL patients, such as survival. We also found that
Rictor (mTORC2) was not overexpressed in Hodgkin-lymphoma biopsies and cell lines. Rapamycin inhibited
proliferation and induced apoptosis in Hodgkin-lymphoma cells both in vitro and in vivo, moreover, it increased the
apoptotic effect of chemotherapeutic agents.
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Conclusions: Targeting mTOR activity may be a potential therapeutic tool in lymphomas. The presence of mTOR
activity probably indicates that the inclusion of mTOR inhibition in the therapy of Hodgkin-lymphomas may be
feasible and beneficial, especially when standard protocols are ineffective, and it may also allow dose reduction in
order to decrease late treatment toxicity. Most likely, the combination of mTOR inhibitors with other agents will
offer the highest efficiency for achieving the best clinical response.
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The number of patients diagnosed with lymphoid malig-
nancies has increased to 18,000 per year in Europe [1].
Hodgkin-lymphomas (HL) with characteristic histopatho-
logical subtypes comprise about 11% of all lymphomas
[1,2]. Tumor cells [Hodgkin-/Reed-Sternberg (HRS) cells]
usually represent only a small fraction of diagnostic
histology, while differences in microenvironment (reactive
lymphocytes, extracellular matrix) allow subclassification
of HL [3,4]. The prognosis of HL patients is relatively
good, however, some patients may relapse in spite of
first line chemotherapy and radiation protocols, and can
be further treated, sometimes cured by intensified chemo-
therapy and/or peripheral stem cell transplantation [5].
Unfortunately, these treatments still fail in 15-20% of HL
patients [6]. Considering that the majority of HL patients
are young and the survivors have a high risk of acute or
late toxicity associated with therapy [7], more efficient and
less toxic therapeutic strategies are needed. Targeting
signaling pathways offers an attractive approach.
The PI3K/Akt/mTOR pathway is activated in a number
of human neoplasms, accompanied by lower overall and
disease free survival [8]. This pathway plays a key role in
the regulation of cellular functions such as survival, proli-
feration, cell death and metabolic activities [9]. mTOR
(mammalian target of rapamycin) – an important compo-
nent of this network – is a serine-threonine kinase, which
exists in two distinct multiprotein complexes (mTORC1
and mTORC2 – containing characteristic elements: Rap-
tor and Rictor, respectively) [10]. The best known targets
of mTORC1 are eukaryotic initiating factor-4E binding
proteins (4EBP) and S6 kinase (S6K). mTORC2 can regu-
late Akt dependent antiapoptotic and survival mecha-
nisms by phosphorylating Akt [11].
The PI3K pathway can be activated by several up-
stream receptors (IGF-R, Flt3, c-Kit, Notch, TCR, BCR)
or intracellular proteins (Ras, BCR/ABL) in various
hematological diseases [12]. Information about mTOR
activity is very limited; however, transforming direct
genetic modifications of PI3K, Akt, mTOR or PTEN are
rare – such mutations occur in 5% of lymphoid malig-
nancies [13]. mTOR has indeed been proven an import-
ant element in tumorigenesis in mantle cell lymphoma(MCL): its role was confirmed in MCL cell proliferation,
mainly by influencing cyclin D1 expression [14]. This
suggests that the mTOR pathway may play an important
role in the development or progression of other lym-
phoma types as well, and can be considered as a useful
therapeutic target.
Rapamycin (and its analogs: rapalogs) interacts with the
FKBP12 protein, an element of the mTOR complex,
and preferentially disrupts mTORC1 activity [15]. The re-
sponse of mTORC2 to rapalogs remains conflicting [16].
Rapalogs have been used as immunosuppressive agents in
organ transplantation since 1999, and they have been in-
troduced into clinical oncology as a treatement option in
renal cell carcinoma and recently in MCL as well [14].
Several trials using mTOR inhibitors in tumors with high
mTOR activity are currently underway [17-19].
The aim of our study was to investigate mTOR activity
in different lymphomas, with a focus on HL. We found
that the majority of HL cases (93%) displays high mTOR
activity. Therefore we suggest that mTOR inhibition (e.g.
by rapalogs) may be considered as a therapeutic option in
HL, especially in patients with poor prognosis/relapse.
Methods
Cell culture
KM-H2, L428, L1236, HDLM2, DEV (Hodgkin-lymphoma)
cell lines were cultured in RPMI 1640 supplemented with
100 U/ml penicillin, 100 ng/ml streptomycin (Sigma) and
heat-inactivated 10% FCS (Gibco). The UH-01 (HL) cell
line was cultured in Iscove's MDM + RPMI-1640 (4:1)
supplemented with 20% FCS, 2 mM L-glutamine (Sigma)
and penicillin and streptomycin as above.
Cells were treated with rapamycin (50 ng/ml, Sigma)
for 72 h; culture medium was refreshed with new medium
supplemented with rapamycin after 72 h to avoid ra-
pamycin concentration decrease (due to metabolic deg-
radation) in longer treatments (96–144 h). Combination
treatments in HL cell lines were done for 72 hours.
Doxorubicin (0.2 μM; Ebewe Pharma), vincristine (10 nM;
Richter Gedeon) and etoposide (1 μM; Pharmachemie BV)
were used in combination with rapamycin. Cell morpho-
logy was evaluated on methanol fixed and hematoxylin-
eosin (HE) stained cytospin preparates.
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Whole cell extracts were prepared and quantitated with
Quant-iT protein assay (Invitrogene). Protein extracts
(112.5 μg) were transferred to PVDF membranes
after SDS-PAGE. Membranes were incubated with anti-
phospho-mTOR (Ser2448), anti-mTOR, anti-phospho-
p70S6K (Thr389) and anti-phospho-S6 (Ser235/236)
antibodies (Cell Signaling), followed by biotinylated sec-
ondary antibodies and avidin-HRP complex (Vectastain
Elite ABC Kit, Vector), and detected by enhanced chemi-
luminescence (Pierce ECL Western Blotting Substrate).
Membranes were stripped (Re-Blot Plus, Millipore) and
reprobed with β-actin (A2228; Sigma) to confirm equal
protein loading.
Enzyme-linked immunosorbent assay (ELISA)
Cell lysates were obtained from isolated normal B- and
T-cells, normal mononuclear cells from buffy coat and
lymphoma/leukemia cell lines (5×106 cells/sample) in
lysis buffer (Cell Signaling) containing 1 mM phenyl-
methylsulfonyl fluoride (PMSF) for 30 minutes on ice.
Sandwich ELISA Kit (p4EBP1 – Thr37/Thr46, Cell
Signaling) was used for the detection of phospho-4EBP1
according to the manufacturer’s instructions. Optical
density (OD) was measured at 450 nm wavelength.
Flow cytometry
For apoptosis detection cells were fixed in 70% ethanol
(−20°C) followed by alkalic extraction (200 mM Na2HPO4,
pH 7.4 and 100 mg/ml RNase; Sigma) and propidium-
iodide staining (1 mg/ml, Sigma) according to Mihalik
et al. [20]. A minimum of 10,000 events/sample were ac-
quired on a FACScan flow cytometer (BD Biosciences,
Erembodegem, Belgium). Data were analyzed with WinList
software (Verity Software House, Topsman, ME, USA).
Tissue microarray (TMA) and Hodgkin-lymphoma patients
Formalin-fixed paraffin-embedded biopsy specimens from
105 lymphoma patients (6 Burkitt-lymphomas [BL], 23
HL, 11 MCL, 9 anaplastic large-cell lymphomas [ALCL], 9
diffuse large B-cell lymphomas [DLBCL], 12 marginal
zone lymphomas [MZL], 13 chronic lymphoid leukemias/
small lymphocytic lymphomas [CLL], 10 follicular lym-
phomas, 12 peripheral T-cell lymphomas) were included
in the first TMA study. The total number of HL patients
was 83 in the second TMA set, which represented all HL
subtypes: nodular lymphocyte predominant (NLPHL) and
classical HL (cHL) types (7 and 76 cases, respectively).
cHL samples included nodular sclerosis (n=47), mixed cel-
lularity (n=18), lymphocyte rich (n=8) and lymphocyte
depleted (n=3) cases. In each case, two representative
cores of 2 mm diameter were selected from different
areas. Reactive lymphoid tissues (tonsils and lymph nodes)
were also included as non-neoplastic controls.Hodgkin-lymphoma patients (40 females, 43 males;
age: 8–82 years [23 patients<18 years, 41 patients: 18–
45 years, 15 patients: >45 years]; mean age: 29.8 years)
were diagnosed at our Institute between 2000 and 2007.
The minimum follow-up period was 5 years in all cases.
Clinical data were available in detail in 72 cases from the
analyzed 83 patients: 59 of these patients were in complete
remission after 5 years of follow-up, 25 patients had re-
lapse and 10 patients died, 13 patients had stem cell trans-
plantation. 60% of these relapsed patients (15/25) are now
in CR, including 8 patients who achieved CR following
stem cell transplantation. The majority (64%) of the pa-
tients had stage I-II disease, whereas 36% presented with
stage III-IV disease; 30% of the patients had B-symptoms.
For pediatric and adolescent patients (8–18 years), treat-
ment group (TG) 1 (stages IA/B, IIA) received 2 cycles
OPPA (females) or OEPA (males); TG2 (stages IIB, IIIA,
IEA/B, IIEA) received 2 cycles OPPA or OEPA and 2
cycles COPP; TG3 (IIIB, IVA/B, IIEB, IIIEA/B) received 2
cycles OPPA or OEPA and 4 cycles COPP. Additional
radiotherapy and/or autologous/allogeneic hematopoietic
stem cell transplantation (HSCT) was given in the case of
incomplete remission. (OPPA: vincristine, procarbazine,
prednisone, doxorubicin; OEPA: vincristine, etoposide,
prednisone, doxorubicin; COPP: cyclophosphamid, vin-
cristine, procarbazine, prednisone).
Adult patients were treated with ABVD; DHAP protocol
was used in the case of ABVD-resistance. DHAP was also
given before HSCT. (ABVD: adriamycin, bleomycin, vin-
blastine, dacarbazine; DHAP: dexamethasone, high dose
cytarabine, cisplatin).
All protocols were approved by the Institutional Ethical
Review Board (TUKEB no. 7/2006).
Immunocytochemistry/Immunohistochemistry (ICC/IHC)
Four μm TMA sections were deparaffinized. Endogenous
peroxidase blocking was followed by antigen retrieval in
sodium citrate (pH=6) buffer in a microwave oven.
Cytospin preparates were fixed in 80% methanol (10’,-
20°C), and incubated with primary antibodies following
endogenous peroxidase blocking.
Slides were incubated overnight at 4°C with phospho-S6
(Ser235/236), phospho-mTOR (Ser2448), phospho-4EBP1
(Thr37/46), phospho-p70S6K (Thr389), phospho-Histone-
H3 (pHH3), cleaved/activated caspase3 (Cell Signaling),
Rictor (Abcam), Raptor (Novus), CD15 (Leica), CD30,
MUM-1, Bcl-xL, Bcl-2 (Dako), NF-kappaB-p50 and
Survivin (LabVision) antibodies.
Primary antibodies were followed by Novolink Polymer
Detection System (Novocastra, Wetzlar, Germany), visual-
ized by DAB and counterstained with hematoxylin. Immu-
nostainings were evaluated by 2 independent pathologists.
3DHistech Pannoramic Viewer program and Nikon E200
were used for tissue microarray analysis.
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phospho-S6 TMA immunostaining reaction intensity
(negative, 1+(weak)/2+(moderate)/3+(strong) positive)
was agreed upon before blind evaluation of the scores
(0/1+/2+/3+). Non malignant, reactive lymphocytes
showed a maximum positivity of 1+, whereas plasma
cells were score 3+.
The most reliable phospho-protein marker for mTOR
activity was phospho-S6, which is supported by literature
data. Therefore, the cases in our study were considered
to have high mTOR activity only when scores were 2+/3+
for phospho-S6 and for at least one additional mTOR ac-
tivity related phosphoprotein (pmTOR, pp70S6K), as de-
scribed previously [21].
NF-kappaB-p50 was considered positive when nuclear
staining was observed; Bcl-2 and Bcl-xL positivity was
cytoplasmic. Survivin showed both nuclear and cytoplas-
mic positivity.pS6
pp70S6Kpp70S6K
pmTOR
pS6
pS6
A B
E F
I J
Figure 1 mTOR activity is increased in lymphoma cells. mTOR activity
Lymphomas with high mTOR activity (2+/3+): Hodgkin-lymphoma (A-D), m
lymphoma (H), anaplastic large-cell lymphoma (I). Lymphomas with low m
chronic lymphoid leukemia/small lymphocytic lymphoma (J), marginal zonThe cutoff for positivity was set at 10% of the tumor
cells staining for the antibodies, according to Sebestyén
et al. [21].
Hodgkin-lymphoma xenograft model
Xenograft tumors were established in SCID mice by
injecting 2×107 KMH2 cells subcutaneously (s.c.) with
matrigel into the back region of 8–10 week old (20–23 g)
mice. Palpable tumors were removed, cut into pieces and
transplanted into secondary recipient mice. When palp-
able s.c. tumors developed (after 8 weeks), animals were
divided into control and rapamycin-treated groups (n=10
each). Rapamycin (Rapamune 1 mg/ml, Wyeth Europa
Ltd.) was administered by gavage at 3 mg/kg body weight
three times per week for 8 weeks. Control groups were
treated with saline. Body weight and tumor diameter was
measured weekly. Tumor volume was calculated as fol-
lows: п/6×(2×shorter diameter + longer diameter)/3)3.p4EBP1
pp70S6K
pp70S6K 
p4EBP1
p4EBP1
pS6
C D
G H
K L
related phosphoproteins in different lymphomas detected by IHC.
antle cell lymphoma (E), Burkitt-lymphoma (F-G), diffuse large B-cell
TOR activity (0/1+) comparable to non malignant lymphoid cells:
e lymphoma (K); control lymph node (L); (IHC), 200X, 400X.
Figure 2 mTOR signaling activity is increased in Hodgkin-lymphoma cell lines. a. The amount of phosphorylated 4EBP1 protein is elevated
in KMH2 Hodgkin-lymphoma cell line compared to normal B-cells, T-cells and buffy coat samples. (ELISA; p<0.05) b. Confirmation of mTOR
activity in HL cell lines (KMH2, L428, UH-01, DEV, L1236, HDML2) by pS6 (A-C) and pmTOR (D-F); ICC (400X). c. mTOR kinase and phosphorylated
proteins related to its activity (pmTOR, pp70S6K and pS6) in Hodgkin-lymphoma cells detected by Western-blotting. mTOR activity is rapamycin-
sensitive in HL cell lines (Co: control; R: rapamycin-treated cells). Representative results showed in KMH2 HL cell line.
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the end of the experiments. Tumor tissues were formalin-
fixed, paraffin-embedded and immunostained with human
CD15, human CD30, cleaved/activated caspase3 and
pHH3. pHH3 and cleaved/activated caspase3 stainings
were analyzed with Mirax Viewer software (analysing 4
areas in each sample).
All experiments involving laboratory animals were done
in accordance with the Guidelines for Animal Expe-
riments of the Office of Agricultural Administration of
Budapest and by the Animal Research Comittee of our
university (permission number: 201/2010).Statistics
Statistics was calculated with paired Student’s t-test, Chi
square test and Fisher’exact test using SPSS (SPSS Inc.,
Chicago, IL, USA) and PAST softwares (PAST free soft-
ware was downloaded from http://folk.uio.no), and log-
rank test using GraphPad software (GraphPad, San Diego,
California, USA).Results
mTOR activity is increased in lymphoma cells
mTOR activity was estimated by immunohistochemistry
(IHC) with antibodies against the active form of mTOR
and its target proteins on tissue microarray (TMA)
sections representing different lymphomas. The evaluation
of the mTOR activity stainings of lymphoma subtypes
showed high mTOR activity in the majority (>50%) of
mantle cell lymphoma (11/11), Burkitt-lymphoma (6/6),
diffuse large B-cell lymphoma (5/9), anaplastic large-cell
lymphoma (8/9) and Hodgkin-lymphoma cases (23/23).
Compared to normal lymphoid tissues, HRS cells showed
2+/3+ positivity in virtually all Hodgkin-lymphoma sam-
ples in this first TMA study set (containing a limited
number of cases). Regarding the analyzed cases of other
lymphoma types, no or only low (0/+) mTOR activity was
detected in marginal zone lymphomas, chronic lymphoid
leukemias/small lymphocytic lymphomas and peripheral
T-cell lymphomas (8/12, 12/13 and 10/12 negative/low,
respectively; Figure 1). IHC results were conflicting in
follicular lymphoma cases, because 7/10 samples were
A B C
a
b
Figure 3 mTOR activity in human Hodgkin-lymphoma biopsies. a. High (A) and low (B) mTOR activity in lymphoma cells of Hodgkin-
lymphoma biopsies. Low mTOR activity is comparable to that of reactive lymph nodes (C). (pS6 IHC; representative examples are shown.)
b. Kaplan-Meier survival curves stratified by mTOR activity: low mTOR and high mTOR groups include 6 and 77 cases respectively (p=0.42).
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but all samples were negative for pS6.
Hodgkin-lymphoma is characterized by high mTOR
activity
HL cell lines – KMH2, UH-01, L428, L1236, HDLM2 and
DEV – showed high mTOR activity by ICC (Figure 2b).
ICC results were confirmed by both Western-blotting and
ELISA in KMH2 cells, and either Western-blotting or
ELISA was performed in the other cell lines as well
(Figure 2).
A second set of TMA was constructed containing bi-
opsy specimens from 83 HL patients. High mTOR activity
was confirmed as a characteristic feature of HL (77/83),
independently from the subtypes (NS: 44/47, MC: 17/18,
LR: 8/8, LD: 3/3, NLPHL: 5/7) (Figure 3a). Non-malignant
lymphoid tissues (tumor infiltrating lymphocytes, reactive
tonsils and lymph nodes) showed low expression (0/1+) of
mTOR-related phospho-proteins. IHC results were com-
pared to the clinical data from 72 patients with long-term
(a minimum of five-year) follow-up; we did not find a sig-
nificant correlation with age, gender, stage, prognosis and
histopathological type. We observed a tendency of correl-
ation with therapeutic response and the present status ofpatients, but it did not reach statistical significance
(p=0.42) (Figure 3b). It should be mentioned that all cases
with low mTOR activity (6/72) were in complete remis-
sion with at least 5-year disease-free survival. Moreover,
high mTOR activity (2+/3+) was detected in the biopsies
of all patients who had poor prognosis and died (11 /72).
However, high mTOR activity was observed in the case of
both favorable and unfavorable clinical response.
We found that the expression of Raptor and Rictor
(characteristic proteins of mTORC1 and mTORC2, re-
spectively) by IHC was similar to the expression pattern
of normal lymphocytes in 82 HL cases (Figure 4a).
Rictor overexpression (2+/3+) (which was detected in
several control breast carcinomas, indicating potential
mTORC2 dominant expression) was detected only in
one HL case.
Anti-apoptotic proteins (Bcl-2, Bcl-xL, Survivin and
NF-kappaB-p50) known to be overexpressed in HLs
were analyzed to search for a potential correlation and
the role of mTOR activity behind their expression in HL
(Figure 4b). High Bcl-xL expression was seen in the
cytoplasm of HRS cells in all cases. NF-kappaB-p50 was
expressed in 70% of HRS cells. 30% and 65% of the ana-
lyzed HL cases showed Bcl-2 and Survivin expression,
aRictor
Raptor
breast cctonsil Hodgkin ly Hodgkin ly
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w
m
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pS6 Survivin NFκB-p50            Bcl-2 Bcl-xLb
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m
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R
Figure 4 Analysis of mTOR related protein expression in HL. a. Hodgkin-lymphomas with no Rictor overexpression. Rictor and Raptor
expression in HRS cells is similar to reactive lymphocytes (0/1+). Rictor expression is 0/1+ in the majority of HL cases (a representative example is
shown); Rictor expression was high only in one HL sample (also shown here; arrows indicate tumor cells). Breast cancer cells show Rictor
overexpression (2+/3+). (IHC, 200X, 400X). b. NF-kappaB-p50 and Bcl-xL expression may corralete to mTOR activity in HLs based on several IHC
stainings; however, this tendency did not reach statistical significance (see results). (Representative IHC stainings are shown in cases with high
and low mTOR activity; 400X).
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ber of mTOR active cases. Based on these results, Bcl-xL
and NF-kappaB-p50 expression may correlate with mTOR
activity in HLs, but we did not find significance with Fish-
er’s exact test (p=0.07 and p=0.86, respectively); however,
statistical analysis was hampered by the low number of
cases with low mTOR activity.
mTOR activity can be targeted in HL cells, leading to
growth inhibition in vitro and in vivo
Rapamycin treatment lead to G1 cell cycle block in all HL
lymphoma cell lines without apoptosis induction after
72 h (Figure 5a). However, a longer (96-144 h) in vitro
rapamycin treatment was able to switch on the apoptotic
program (Figure 5b). The level of phosphorylated S6 wasremarkably decreased, further supporting the inhibition of
mTOR activity in HL cell lines (Figure 2c).
We investigated the effect of rapamycin combined
with chemotherapeutic agents in KMH2, DEV and
L1236 HL cell lines. When given in combination,
rapamycin significantly increased the apoptotic effect of
low dose “traditional” chemotherapeutic agents (doxo-
rubicin, vincristine and etoposide) in KMH2 and DEV
cell lines (Figure 5c). Rapamycin treatment had only an
antiproliferative effect in L1236 cells, and could not en-
hance apoptosis induced by chemotherapeutic agents.
The in vivo growth inhibitory effect of rapamycin was
also confirmed in SCID mice with KMH2 Hodgkin-
lymphoma xenografts. Rapamycin treatment (8 weeks)
significantly reduced tumor volume and tumor weight in
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Figure 5 Anti-proliferative and apoptotic effects of rapamycin in vitro. a. G1 cell cycle arrest detected by flow cytometry after 72 h
rapamycin treatment (50 ng/ml) in KMH2 Hodgkin-lymphoma cells. b. The apoptotic effect of rapamycin is time dependent in KMH2 cells (flow
cytometry, *:p<0.05). c. Rapamycin treatment increased the apoptotic effect of chemotherapeutic agents in HL cell lines after 24 h. A
representative experiment in KMH2 cells is shown here. (R: rapamycin 50 ng/ml, D: doxorubicin 0.2 μM, V: vincristine 10 nM, Eto: etoposide 1
μM; *:p<0.05).
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weight was 0.65 g vs. 0.25 g in the control vs. treated
group, respectively. The significant anti-proliferative and
apoptotic effect of in vivo treatment was also confirmed
in KMH2 xenograft biopsies: the number of phospho-
Histone H3 (pHH3; mitotic marker) positive cells were
decreased (30% compared to control) and the number ofcleaved/activated caspase3 (apoptotic marker) positive
cells were increased (7.3× compared to control) in treated
tumors (Figure 6b).
Discussion
The introduction of new drugs has to be based on con-
vincing evidence in malignancies where clinical response
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Figure 6 Rapamycin inhibits tumor growth in vivo. a. Rapamycin inhibits tumor growth in KMH2 (Hodgkin-lymphoma) xenografts in vivo.
Tumor volumes are shown in control and rapamycin-treated mice during an 8-week treatment. Tumor weight at the end of the experiment is
also indicated; tumors in rapamune treated mice were significantly smaller (p<0.05). b. Confirmation of the in vivo anti-proliferative and apoptotic
effect of rapamycin by IHC detection of pHH3 (proliferation marker) and cleaved/activated caspase3 (apoptosis marker) (*:p<0.05, **:p<0.01).
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is Hodgkin-lymphoma (HL); in fact, no new drugs have
been approved by the FDA for HL in the last 30 years
[22]. However, treatment failures in patients with ad-
vanced disease, insufficient response (recurrences and
resistance) as well as late toxicity of the currently used
chemotherapy – including second malignancies, cardio-
vascular toxicity and infertility – requires improvement
in standard options for treating HL [23]. Targeted the-
rapy is an innovative research field in oncology, where
the defects of major regulatory steps fine-tuning critical
cell functions such as survival, proliferation and apop-
tosis serve as molecular targets.
There is substantial evidence highlighting the import-
ance of changes in the activity of different PI3K pathway
members, including mTOR complexes. Here we show
that mTOR activity is a characteristic feature in the ma-
jority (>50%) of MCL, BL, DLBCL, ALCL and HL cases.High mTOR activity of HRS cells is further supported
by our second TMA study focusing on HLs.
Previous publications reported only small numbers of
cases without considering subclassification of HL
[24,25]. Based on the evaluation of different downstream
mTOR target proteins in 83 HL cases, increased mTOR
activity was confirmed in more than 90% of HLs in our
work, which was independent of HL subtype and clinical
parameters. Low mTOR activity cases had no relapse,
and these patients had more than 5 year disease free sur-
vival, with complete remission. However, high mTOR
activity was observed in the case of both favorable and
unfavorable clinical response, therefore it cannot be con-
sidered as a prognostic indicator. We are aware that the
83 HL patients included in our study comprise a hetero-
geneous patient group in respect of age, gender, stage,
histological type and prognosis. Therefore, it is difficult
to reach significant conclusions; nevertheless, our study
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group, which is obviously characterized by high mTOR
activity in general.
At a molecular level, mTOR activity is known to play
a role in cyclin D1 overexpression and cell cycle
dysregulation in MCL [14]. Through the regulation of
translation or by directly influencing the activity of
p70S6K, mTOR can induce the antiapoptotic functions
of mitochondrial proteins, e.g. by BAD phosphorylation,
supporting the survival and proliferation of tumor cells
[26]. The malfunction of apoptotic pathways and the
overexpression of several cyclins (cyclin A, B1 and E)
are also known in HL [27]. The overexpression of
antiapoptotic signals (Bcl-xL) showed correlation with
high mTOR activity in our study.
Each time a protein known to be a member of regula-
tory signaling pathways, participating in the develop-
ment and/or progression of malignancies is brought into
focus, the question arises: can we turn our knowledge to
therapeutic advantage? In the case of mTOR, inhibitors
already exist (rapamycin and its analogs: rapalogs),
which are well tolerated [28], and rapamycin has also
been shown to synergize with anticancer agents in se-
veral tumors [12,29-31]. Rapalogs/rapamycin inhibited
proliferation and induced apoptosis, moreover, they in-
creased the apoptotic effect of chemotherapeutic agents
(doxorubicin, vincristine and etoposide) in HL cells in our
xenograft and in vitro experiments. These results – along
with others [32-35] – suggest that mTOR inhibition is an
option in tumors with increased mTOR activity. In this
respect HL could be a good candidate, as high mTOR
activity and mTORC1 expression could be detected in a
high percentage of cases, and mTORC1 inhibition also
had an antiproliferative and apoptotic effect in vitro and
in vivo.
The efficiency of mTOR inhibitors may be dependent
on the ratio of mTOR complexes [36]. While mTORC1 is
sensitive to currently used mTOR inhibitors, the rapalog
sensitivity of mTORC2 is still conflicting, and may vary
in different cell types [37,38]. New dual inhibitors –
inhibiting both mTOR complexes, or mTORC1 and up-
stream elements of the PI3K/Akt/mTOR pathway – are
being developed [39]. The inclusion of upstream proteins
is quite logical, because the inhibition of mTORC1 may
be able to activate them. The immunohistochemical de-
tection of the phosphorylated forms of Akt (specifically,
Ser473, which is connected to mTORC2) is very difficult.
We tested different antibodies but we could not detect
realiably specific staining in our lymphoid tissues. Baker
et al. investigated the stability of phosphorylated Akt and
they established that postoperative surgical samples may
be of limited value for measuring phospho-Akt levels be-
cause Akt can be dephosphorylated quickly during tumor
removal and fixation [40]. Considering this, we chose toinvestigate the expression of Rictor, one essential com-
ponent of functioning mTORC2. We concluded that
mTORC2 was not a characteristic feature when Rictor
expression was not detected in the samples. Several solid
and lymphoid malignancies such as non-GC DLBCLs
overexpress Rictor (a characteristic protein in mTORC2),
which potentially indicates increased mTORC2 activity
[21,41,42]. Rictor was not overexpressed in our HL cell
lines and cases, which can explain the sensitivity to
rapamycin/rapalogs.
Taken together, Hodgkin-lymphoma is characterized by
high mTOR activity, and this high mTOR activity does
not exclude good prognosis. Moreover, mTORC1 may be
a potential therapeutic target in HL, especially when com-
monly used protocols prove ineffective, and may also
allow dose reduction of chemotherapeutic drugs in order
to decrease late toxicity without diminishing treatment
efficacy. The combination of mTOR inhibitors with other
agents targeting critical molecular sites will likely be cru-
cial for achieving the best clinical response.
Conclusion
Based on our results, mTOR activity may be a potential
therapeutic tool in different lymphoma types. In particular,
the majority of Hodgkin-lymphomas have high mTOR ac-
tivity (with no mTORC2/Rictor expression). These data,
along with our in vitro and in vivo results with mTOR in-
hibitors suggest that the inhibition of mTORC1 may be
feasible in the therapy, especially in Hodgkin-lymphomas
when standard protocols prove ineffective. The combi-
nation of mTOR inhibitors with other agents will probably
offer the highest efficiency for achieving the best clinical
response, and may also allow dose reduction in order to
decrease late treatment toxicity in these cases.
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